- 6MWD improvement was apparent as early as 8 weeks and was sustained at weeks 12 and 162
*33 meters is approximately 108 feet.
†Includes patients on monotherapy and background bosentan therapy.2,3
PROVEN RESULTS AS MONOTHERAPY2,3
- ADCIRCA significantly improved 6MWD vs placebo in the monotherapy subgroup2,3
*44 meters is approximately 144 feet.
STUDIED FOR USE WITH BACKGROUND BOSENTAN2,3
- 53% of patients were on background therapy with bosentan in the PHIRST-1 pivotal trial2,3
DECREASED CLINICAL WORSENING2,3
- ADCIRCA reduced the risk of clinical worsening vs placebo at 16 weeks.2,3
- Clinical worsening is defined as death, lung transplantation, atrial septostomy, hospitalization because of worsening PAH, initiation of new PAH therapy (prostacyclin or analog, endothelin receptor antagonist, PDE-5 inhibitor), or worsening WHO functional class.3
LONG-TERM RESULTS2
- In a long-term extension study, at a median of 356 days (N=357), the survival rate was 96.5 per 100
patient-years. Without a control group, these data must be interpreted cautiously3